Dual WEE1/YES1 Kinase Inhibitor MRANK-106 Secures FDA IND Clearance, Positioning MindRank in First-in-Class Oncology Pipeline
Based on extensive preclinical studies, MRANK-106 is differentiated from other WEE1 inhibitors in development by its: Dual targeting of WEE1 and YES1 kinases, providing synergistic anti-tumor effects ...
MyChesCo on MSN8d
Aprea Therapeutics Teams Up with MD Anderson for Preclinical HNSCC Research
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has entered into a Material Transfer Agreement (MTA) with MD ...
Targeted Oncology13d
FDA Clears Phase 1 Trial of MRANK-106 in Advanced Solid Tumors
The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced ...
BioWorld11d
Mindrank’s dual WEE1 and YES1 kinase inhibitor cleared to enter clinic in US
Mindrank Ltd. has announced that the FDA has cleared the company’s IND application for MRANK-106, a potentially first-in-class, orally available dual inhibitor of WEE1 and YES1 kinases, for the ...
Nature1mon
Cancer target back in contention with more selective inhibitor
“There’s pretty good preclinical evidence that there is synergistic activity when radiation therapy, and possibly also alkylating chemotherapy, is combined with a WEE1 inhibitor,” says Roth.
Taiwan News5d
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...
Yahoo Finance14d
Dual WEE1/YES1 Kinase Inhibitor MRANK-106 Secures FDA IND Clearance, Positioning MindRank in First-in-Class Oncology Pipeline
We look forward to evaluating its potential in patients." MRANK-106 is a novel, orally available dual inhibitor of WEE1 and YES1 kinases discovered using MindRank's proprietary AI platforms.